Expert witnesses were pitted against each other Wednesday at a trial alleging generic makers infringed a patent covering the anti-depressant Lexapro, and Apotex’ consultant took the brunt of it.
The corporate regulator has confirmed it is investigating AMP over its ‘fees for no service’ practice revealed at the Hayne Royal Commission in stunning testimony Treasurer Scott Morrison on Wednesday called “deeply disturbing”.
A former NAB financial adviser has been permanently banned from providing financial services after an ASIC investigation found he fleeced clients out of at least $2 million.
A judge has dismissed a second defamation case against Fairfax Media brought by an associate of a murdered Sydney businessman, ruling the plaintiff waived his right to sue again after dropping an earlier suit against the publisher for a $75,000 payout.
A barrister for the Australian Writers’ Guild has blasted documents produced by the non-profit Screenrights in a court battle over tens of millions of dollars in royalties payments, calling the evidence a “complete mishmash”.
Two high ranking analysts from S&P Global have distanced themselves from the decision making process at the heart of a class action over toxic financial products given healthy ratings by the agency ahead of the global financial crisis.
The independence of a report by law firm Clayton Utz to ASIC over AMP’s practice of charging customers for services not performed was called into question Tuesday at the Hayne Royal Commission.
Two Commonwealth Bank subsidiaries have entered an agreement with ASIC to pay $3 million for failing to provide annual reviews to customers that paid for the service, adding to the $88 million they have already paid out to 31,500 affected customers.
A BHP subsidiary has won a reprieve pending appeal of a Fair Work Commission decision that found it acted unreasonably when it failed to consider alternative work for an incapacitated miner.
The maker of the anti-depressant Lexapro faced off Monday against Apotex, Aspen Pharma and Sandoz at a court hearing over the rights to make generic versions of the top-selling product, with a barrister for Lundbeck slamming the three companies’ defence that their drugs were different.